{"created":"2023-06-20T13:45:31.025511+00:00","id":290,"links":{},"metadata":{"_buckets":{"deposit":"3edf11c0-80aa-4079-915e-d269049d51be"},"_deposit":{"created_by":12,"id":"290","owners":[12],"pid":{"revision_id":0,"type":"depid","value":"290"},"status":"published"},"_oai":{"id":"oai:khsu.repo.nii.ac.jp:00000290","sets":["22:81:93"]},"author_link":["473","334","475","471","474","472"],"item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2022-03","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"19","bibliographicPageEnd":"86","bibliographicPageStart":"77","bibliographic_titles":[{"bibliographic_title":"熊本保健科学大学研究誌"},{"bibliographic_title":"Journal of Kumamoto Health Science University","bibliographic_titleLang":"en"}]}]},"item_10002_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"　多発性骨髄腫 （multiple myeloma : MM） に対する抗ヒト CD38 抗体であるdaratumumab（DARA） 投与中の患者検体では，間接抗グロブリン試験 （indirect antiglobulin test : IAT） が偽陽性となる可能性がある。今回，dithiothreitol （DTT） を使用しない，DARA の干渉を回避する新たな検出法を開発することを目的として検討を行った。\n　DARA と赤血球の結合を評価するために，各濃度のDARA 存在下で CD38 の発現を flow cytometry で測定したところ，CD38 の mean fluorescence intensity （MFI） は DARA 添加により低下した。さらに，DARA と His-tag 結合 recombinant human CD38 protein（ H-rhCD38）を反応させ，磁気ビーズを用いて上清から DARA の除去を検討した結果，DARA により阻害されていたAPC- 抗CD38 抗体の赤血球への結合が，DARA の除去により回復された。\n　これらの結果から，DARA 投与中の MM 患者の血清に H-rhCD38 を添加し，磁気ビーズで除去することで，DARA の IAT への干渉を回避できる可能性が示唆された。","subitem_description_type":"Abstract"}]},"item_10002_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"熊本保健科学大学"}]},"item_10002_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"24335002","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorAffiliations":[{"affiliationNameIdentifiers":[{"affiliationNameIdentifier":"","affiliationNameIdentifierScheme":"ISNI","affiliationNameIdentifierURI":"http://www.isni.org/isni/"}],"affiliationNames":[{"affiliationName":"","affiliationNameLang":"ja"}]}],"creatorNames":[{"creatorName":"登尾, 一平","creatorNameLang":"ja"},{"creatorName":"ノボルオ, イッペイ","creatorNameLang":"ja-Kana"}],"familyNames":[{"familyName":"登尾","familyNameLang":"ja"},{"familyName":"ノボルオ","familyNameLang":"ja-Kana"}],"givenNames":[{"givenName":"一平","givenNameLang":"ja"},{"givenName":"イッペイ","givenNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"334","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"木村, 契太"}],"nameIdentifiers":[{"nameIdentifier":"471","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"中尾, 沙希"}],"nameIdentifiers":[{"nameIdentifier":"472","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"松形, 僚也"}],"nameIdentifiers":[{"nameIdentifier":"473","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"川口, 辰哉"}],"nameIdentifiers":[{"nameIdentifier":"474","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"上妻, 行則"}],"nameIdentifiers":[{"nameIdentifier":"475","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2022-03-29"}],"displaytype":"detail","filename":"p077-086-noboruo.pdf","filesize":[{"value":"1.7 MB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"p077-086-noboruo","url":"https://khsu.repo.nii.ac.jp/record/290/files/p077-086-noboruo.pdf"},"version_id":"cb8203aa-6640-4296-9e9b-94449bae6503"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"daratumumab （DARA）","subitem_subject_scheme":"Other"},{"subitem_subject":"間接抗グロブリン試験","subitem_subject_scheme":"Other"},{"subitem_subject":"flow cytometry","subitem_subject_scheme":"Other"},{"subitem_subject":"recombinant human CD38 protein","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"間接抗グロブリン試験における daratumumab の影響を回避する 新たな方法のための基礎研究","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"間接抗グロブリン試験における daratumumab の影響を回避する 新たな方法のための基礎研究"},{"subitem_title":"A basic study to establish a new method to avoid the effects of daratumumab in indirect antiglobulin test","subitem_title_language":"en"}]},"item_type_id":"10002","owner":"12","path":["93"],"pubdate":{"attribute_name":"公開日","attribute_value":"2022-04-02"},"publish_date":"2022-04-02","publish_status":"0","recid":"290","relation_version_is_last":true,"title":["間接抗グロブリン試験における daratumumab の影響を回避する 新たな方法のための基礎研究"],"weko_creator_id":"12","weko_shared_id":-1},"updated":"2025-05-14T01:13:00.582549+00:00"}